Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of new drugs. Founded on June 12, 1995, the company has been developing and expanding continuously over the years. With the strong support of the state, provincial and municipal governments, the company successfully completed the shareholding system reform in 2, and successfully listed on the Shanghai Stock Exchange on March 8, 24 (stock code 6594), becoming the first non-public pharmaceutical enterprise in Guizhou Province to obtain the listing qualification.
the company covers an area of 134,398 square meters, and has built 43,2 square meters of production workshops conforming to the national good manufacturing practice (GMP for short), with a green area of 12, square meters. The production lines of capsules, tablets, syrups, small-volume injections and freeze-dried powder injections owned by the company have passed the national GMP certification, and all production lines have reached the domestic advanced level.
in p>21, the company achieved an industrial output value of 2 billion yuan, a sales income of 1.467 billion yuan, and paid taxes of 298 million yuan for the country. Since the restructuring in 2, the company has paid a total of 1.322 billion yuan in taxes, which has made remarkable achievements and become a pillar industry of local economic development and an important source of local fiscal revenue in Guizhou.
during its development, the company has been committed to improving corporate governance and constantly improving its level. The company has formulated the standard Articles of Association and the rules of procedure of the "Three Meetings", implemented the independent director system, set up the strategic development committee, the audit committee, the nomination committee and the remuneration and assessment committee, formulated a strict and standardized financial system and information disclosure system, and formed a set of management mechanism with clear rights and responsibilities and checks and balances of power, which provided institutional guarantee for the company's sustained and healthy development.
The company has more than 5,2 employees, of whom those with college education or above account for 78% of the total. In line with the concept of "cultivating people for a hundred years", the company has established a systematic training system to comprehensively improve the quality of employees.
in March, 24, the company used 12 million study funds to jointly run a school with Antai School of Management of Shanghai Jiaotong University, and established Guiyang Class of Antai School of Management of Shanghai Jiaotong University. Fifty middle-level management cadres of the company became EMBA students in this class, which was a successor force for the company's development reserve management. The company also sent professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating innovative spirit; Adhere to the workers' training system, and constantly strengthen the improvement of workers' cultural quality, self-cultivation and technical skills. The employees of the whole company are trained in strict accordance with more than 3 hours per year.
In the economic crisis in 28, Yibai not only didn't reduce production and lay off employees, but also expanded the employment and absorbed the social labor force, making due contributions to social stability and development.
At present, the company's main products include Aidi injection, Yinxingdamo injection (Xingding injection), Compound Mylabris capsule (Kangsaidi capsule), Keke capsule, Ganmao Zhike syrup, Shugan Yiyang capsule, Jingulian capsule, Luobo injection, etc., which have formed a series of products with enterprise advantages. Among them, Aidi Injection and Compound Mylabris Capsule (Kangsaidi Capsule) are new biphasic anti-tumor drugs, and the research on Aidi Injection, a compound traditional Chinese medicine injection, has reached the gene level. The fourth generation Ginkgo biloba preparation-Yinxingdamo injection (Xingding injection) is an effective drug for treating cardiovascular, cerebrovascular and peripheral circulation disorders, and its development and production have injected new vitality into the company. Loplatin injection is the third generation platinum antineoplastic drug in tumor chemotherapy. Compared with other platinum antineoplastic drugs, it has the advantages of no nephrotoxicity, ototoxicity and neurotoxicity, and it has no cross-resistance with other platinum drugs.
for a long time, the company has always attached great importance to the promotion of technological innovation and scientific research and development to enterprises, emphasizing that "science and technology is the driving force for the company's progress". In 25, the company won the title of "National Excellent Private Technological Innovation Enterprise". In 26, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs and the State Administration of Taxation awarded our company the "National Certified Enterprise Technology Center". The center has made some achievements in the research, development and production of new products such as traditional Chinese medicine injections, oral liquid preparations, and new solid preparations such as orally disintegrating tablets, effervescent tablets, sustained and controlled release preparations, and has great advantages in the industry. In 26, the company was approved by the Ministry of Personnel as a postdoctoral workstation for enterprises. In 27, with the approval of the Science and Technology Department of Guizhou Province, our company was established as the Engineering Technology Research Center of New Drug Release System in Guizhou Province. In 28, it was approved as a national innovative pilot enterprise, and was also rated as a high-tech enterprise in Guizhou Province in the same year. In 28, with the approval of the Development and Reform Commission of Guizhou Province, our company also obtained the Engineering and Technology Center for New Preparations of Ethnic Medicine in Guizhou Province, and received the financial and technical support from the state. In 29, the company was approved as a national innovative enterprise, and in the same year, it was awarded the "National and Local Joint Engineering and Technology Research Center for New Preparations of Southwest Ethnic Medicine" by the National Development and Reform Commission. On this basis, our company is actively increasing product research and development, and many projects are carried out in an orderly manner in new product development and dosage form modification. At present, the company has 41 varieties of * * * under research, including 13 cardiovascular and cerebrovascular diseases, 4 anti-tumor diseases, and 9 cold and cough diseases. Six kinds of new drugs of traditional Chinese medicine developed by the company have entered the third clinical stage, which will become a new profit growth point for the company in the future and inject new vitality into the company. Among them, Compound Herba Polygoni Cuspidati and Miyixinle Dropping Pills have great market potential.
The company has always attached great importance to the protection of intellectual property rights. In 24, it set up a special intellectual property department, and adopted measures such as applying for patent protection and creating well-known trademarks, focusing on developing core technologies and enhancing the independent innovation ability of enterprises. The company has applied for 229 patents, and 112 have been authorized, including 91 invention patents and 21 design patents. 22 trademarks were applied for and 183 were obtained. And three main trademarks, Yibai, Zuozuyibai and Keke, were registered in Madrid, and trademarks were registered in 26 countries. "Yibai" and "KEKE Keke" were well-known trademarks in China, and "Zuozu Yibai" was well-known trademarks in Guizhou Province. The core product "Aidi Injection" with independent intellectual property rights won the 1th National Patent Excellence Award in 28. Guizhou Yibai Pharmaceutical was listed as the first batch of enterprises with intellectual property advantages in Guizhou Province and the fourth batch of pilot units of intellectual property rights in China. The number of patent applications and trademark applications ranks first in the same industry in the province, ranking first in the same industry in China.
after successfully acquiring Lijiang pharmaceutical in Guilin and Nanzhao pharmaceutical in Yunnan, we successfully acquired Guizhou ethnic pharmaceutical. And from this year on, we will implement the collectivization operation mode and optimize enterprise management.
under the care and leadership of all levels in Guizhou province and city, the "Guizhou Miao Medicine Group" was established. The company controls Miao Medicine Group by injecting capital into the company's brand and network; Assets and/or products of other enterprises are invested in enterprises. In September, 21, the company jointly recruited the first batch of Miao medicine graduate students in Beijing University of Chinese Medicine as the talent resource reserve of Miao medicine group. The establishment of Miao Medicine Group aims at the characteristics of traditional Chinese medicine and ethnic medicine industry in Guizhou, which greatly enhances the position of Miao medicine in China pharmaceutical industry and promotes the development of local pharmaceutical and Miao medicine enterprises in Guizhou.
Yibai Pharmaceutical has always been involved in public welfare undertakings. In the freezing disaster in early 28, Yibai immediately sent condolences to the people in the disaster area and donated 6, yuan to support the disaster area. In the Wenchuan earthquake in Sichuan in May 28, we rushed to the front and donated 1.24 million yuan in cash and 1 million yuan worth of medicines to our compatriots in the disaster area. In the drought disaster in Guizhou at the beginning of this year, 2.8 million yuan was donated in cash; And establish Hope Primary School in Hezhang County, a national poverty-stricken county.
the company takes "excellent medical product provider and health service leader" as its mission, and adheres to the values of "health 1, quality 1, gratitude 1 and innovation 1" in the tide of economic market, providing customers with high-quality and efficient products that meet environmental protection requirements, creating the greatest wealth for investors and the greatest value for society. To "become a respected company with sustainable management potential in China pharmaceutical industry". Located at No.22-1, Baiyun Avenue, Guiyang City, 8 kilometers away from Guiyang City. Covers an area of 134,398 square meters.